- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Acute tubular necrosis.
Displaying page 1 of 1.
EudraCT Number: 2017-004301-41 | Sponsor Protocol Number: P170404J | Start Date*: 2018-10-15 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS [...] | |||||||||||||
Full Title: FURosemide Stress Test to predict need of Renal Replacement THERapy in Ischemic Acute Tubular Necrosis in Intensive Care Units | |||||||||||||
Medical condition: FURosemide Stress Test to predict need of Renal Replacement THERapy in Ischemic Acute Tubular Necrosis in Intensive Care Units | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004756-38 | Sponsor Protocol Number: 2018-1201 | Start Date*: 2019-02-12 |
Sponsor Name:Institut de Cancérologie Lucien Neuwirth | ||
Full Title: Study of thromboelastography during tranexamic acid treatment in preventing bleeding in patients with haematological malignancies presenting severe thrombocytopenia (TTRAP-bleeding) | ||
Medical condition: Malignant hemopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019126-13 | Sponsor Protocol Number: CE-US | Start Date*: 2011-03-04 | |||||||||||
Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||
Full Title: A PILOT, EXPLORATIVE STUDY TO IDENTIFY CONTRAST-ENHANCED ULTRASOUND (CE-US) PATTERNS THAT CHARACTERIZE ACUTE ALLOGRAFT REJECTION AND OTHER CAUSES OF ACUTE ALLOGRAFT DYSFUNCTION IN RENAL TRANSPLANT ... | |||||||||||||
Medical condition: Renal transplant | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005855-19 | Sponsor Protocol Number: BCX9930-211 | Start Date*: 2021-10-11 | |||||||||||||||||||||
Sponsor Name:BioCryst Pharmaceuticals Inc | |||||||||||||||||||||||
Full Title: An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy | |||||||||||||||||||||||
Medical condition: complement 3 glomerulopathy immunoglobulin A nephropathy primary membranous nephropathy | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) HU (Completed) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
